Skip to content

Board of Directors

lidds-Jan-Tornell-people

Jan Törnell

Chairman of the Board since 2015

Born: 1960

Education: MD and PhD in Physiology, University of Gothenburg

Other assignments: CEO and board member of AB Innoext. Chairman of Glactone Pharma AB and Glactone Pharma Development AB, board member of Abliva AB and Diaprost AB

Work experience: Former Vice President of Global Strategy for AstraZeneca Oncology & Infection. Professor of Physiology at the Sahlgrenska Academy, University of Gothenburg. Partner in P.U.L.S. and member of the investment committee. Associate professor in Physiology, Gothenburg University.

Holdings: 52 909 shares, 0 warrants

Independent in relation to LIDDS AB (publ), its management and the principal shareholders

lidds-David-Bejker-people

David Bejker

Board member since 2019, Chairman of the Audit committee

Born: 1975

Education: MSc from the Stockholm School of Economics

Other assignments: CEO of Affibody Medical AB and board member of Abliva AB and Amylonix AB

Work experience: CEO of Affibody Medical AB, a company that develops innovative protein drugs, since 2008. Previously at HealthCap, a specialized life science investor.

Holdings: 5 624 shares, 0 warrants

Independent in relation to LIDDS AB (publ), its management and the principal shareholders

lidds-Anders-Bjartell-people

Anders Bjartell

Board member since 2015

Born: 1959

Education: MD and PhD in Medical cell research from Lunds University

Other assignments: Professor and Research group leader, Department of Translational Medicine, Division of Urological Cancers, Medical faculty, Lund University. Senior Consultant, Department of Urology, Skåne University Hospital Malmö, Board member and co-Founder of Glactone Pharma AB. Board member of EAU (European Association of Urology) and of EAU Guidelines Office, Chairman of EAU Research Foundation.

Work experience: European Specialist Degree in Urology (FEBU). Visiting Investigator at Memorial Sloan-Kettering Cancer Center in New York 2005 – 2007, Head of Clinical Trials at the Department of Urology, Skåne University Hospital. National Principal Investigator for Several New Drugs for Advanced Prostate Cancer. Published more than 337 Peer Reviewed Articles (Pubmed) with an H-index of 60 in Web-of-Science and 76 in Google Scholars.

Holdings: 13 724 shares, 0 warrants

Independent in relation to LIDDS AB (publ), its management and the principal shareholders

 

lidds-Ingalill-Forslund-people

Ingalill Forslund Larsson

Board member since 2015, member of the Audit Committee

Born: 1954

Education: Bachelor’s degree in business administration with a focus on marketing from Uppsala University. Licensed Midwife and nurse

Other assignments: Board member and CEO Ellet Assets AB, Fastighets AB Olshög, Nible Invest AB, NöbbeGård Projekt AB (own companies)

Work experience: Board member of Lund University BioScience AB, Scandinavian Chemotech AB, Truly Labs AB, Truly Translational AB, Lisberg KB, BCRC AB. Chairman of the Board of XImmune AB, sales and marketing from the pharmaceutical industry, including business area responsibility for Urology, Global Marketing at Ferring Pharmaceuticals and various commercial roles within AstraZeneca.

Holdings: 12 749 shares, 0 warrants

Independent in relation to LIDDS AB (publ), its management and the principal shareholders

 

lidds-Maria-Forss-people

Maria Forss

Board member since 2015, member of the Audit Committee since 2021

Born: 1972

Education: Master’s degree in Economics from the School of Business, Economics and Law at Gothenburg University and Concordia University, Montreal. Executive education at Stanford University, USA. Certified board member via Styrelseinstitutet and advanced board training via StyrelseAkademin

Other assignments: Senior Vice President Consumables Division, Vitrolife

Work experience: Vice President Business Development and Global Marketing at Vitrolife. Board member of Oncorena AB. Head of Business Development of Aquilion (former P.U.L.S.), CEO Duocort Pharma and management roles within Astra Zeneca.

Holdings: 26 186 shares, 0 warrants

Independent in relation to LIDDS AB (publ), its management and the principal shareholders

lidds-Daniel-Lifveredson-people

Daniel Lifveredson

Board member since 2017

Born: 1976

Education: Master of Science in Industrial Engineering and Management, Chalmers University of Technology in Gothenburg

Other assignments: CEO and owner of Excore AB

Work experience: Worked with Excore as a base since 1998. Excore is active in advising corporate transactions in the segment of medium-sized companies. Long experience in international business. In addition to Excore, Daniel Lifveredson is involved as a partner in a number of businesses.

Holdings: 2 640 929 shares, 0 warrants

Independent in relation to LIDDS AB (publ), its management and the principal shareholders